Clare Market Investments LLC Purchases 1,088 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Clare Market Investments LLC increased its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 22.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,932 shares of the medical equipment provider's stock after buying an additional 1,088 shares during the quarter. Intuitive Surgical comprises approximately 0.8% of Clare Market Investments LLC's portfolio, making the stock its 22nd biggest holding. Clare Market Investments LLC's holdings in Intuitive Surgical were worth $2,938,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the business. Portside Wealth Group LLC lifted its holdings in shares of Intuitive Surgical by 17.0% during the 1st quarter. Portside Wealth Group LLC now owns 1,356 shares of the medical equipment provider's stock worth $708,000 after acquiring an additional 197 shares during the period. Park Edge Advisors LLC increased its position in Intuitive Surgical by 110.4% during the first quarter. Park Edge Advisors LLC now owns 2,348 shares of the medical equipment provider's stock worth $1,163,000 after purchasing an additional 1,232 shares during the last quarter. Veracity Capital LLC raised its stake in Intuitive Surgical by 3.9% during the first quarter. Veracity Capital LLC now owns 607 shares of the medical equipment provider's stock worth $301,000 after purchasing an additional 23 shares during the period. TrueWealth Advisors LLC boosted its holdings in shares of Intuitive Surgical by 4.1% in the 1st quarter. TrueWealth Advisors LLC now owns 1,079 shares of the medical equipment provider's stock valued at $534,000 after purchasing an additional 42 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. grew its stake in shares of Intuitive Surgical by 16.4% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 15,405 shares of the medical equipment provider's stock valued at $7,630,000 after buying an additional 2,168 shares during the period. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Intuitive Surgical Price Performance

Shares of Intuitive Surgical stock traded down $0.98 on Friday, hitting $557.08. The company had a trading volume of 1,103,774 shares, compared to its average volume of 1,642,177. The business has a 50-day simple moving average of $520.78 and a 200-day simple moving average of $539.13. The company has a market cap of $199.67 billion, a PE ratio of 86.91, a PEG ratio of 5.85 and a beta of 1.67. Intuitive Surgical, Inc. has a 52 week low of $405.08 and a 52 week high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.71 by $0.10. Intuitive Surgical had a return on equity of 14.55% and a net margin of 27.81%. The company had revenue of $2.25 billion for the quarter, compared to analyst estimates of $2.19 billion. During the same period in the previous year, the firm earned $1.50 earnings per share. On average, equities research analysts predict that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

ISRG has been the topic of several research reports. Truist Financial cut their target price on Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. BTIG Research set a $560.00 price objective on Intuitive Surgical and gave the stock a "buy" rating in a report on Monday, April 14th. Robert W. Baird decreased their target price on Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating for the company in a report on Wednesday, April 23rd. Citigroup restated a "buy" rating and issued a $650.00 price target (up previously from $590.00) on shares of Intuitive Surgical in a report on Thursday, May 22nd. Finally, Evercore ISI decreased their price objective on shares of Intuitive Surgical from $510.00 to $470.00 and set an "in-line" rating for the company in a research note on Wednesday, April 23rd. Four equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat, Intuitive Surgical currently has an average rating of "Moderate Buy" and an average price target of $596.05.

Insider Activity

In other news, EVP Robert Desantis sold 11,545 shares of the stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $499.22, for a total transaction of $5,763,494.90. Following the transaction, the executive vice president now owns 5,224 shares in the company, valued at $2,607,925.28. This represents a 68.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Brian Edward Miller sold 8,900 shares of Intuitive Surgical stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $485.07, for a total transaction of $4,317,123.00. Following the completion of the sale, the executive vice president now directly owns 5,758 shares of the company's stock, valued at approximately $2,793,033.06. The trade was a 60.72% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 25,443 shares of company stock worth $12,692,195. 0.70% of the stock is owned by corporate insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.